Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

The STING of radiation

21.11.2014

Ludwig researchers reveal the molecular mechanisms by which the immune system is activated against tumors treated with radiation

A team of researchers led by Ludwig Chicago's Yang-Xin Fu and Ralph Weichselbaum has uncovered the primary signaling mechanisms and cellular interactions that drive immune responses against tumors treated with radiotherapy. Published in the current issue of Immunity, their study suggests novel strategies for boosting the effectiveness of radiotherapy, and for combining it with therapies that harness the immune system to treat cancer.

"Much of the conversation about the mechanisms by which radiation kills cancer cells has historically focused on the damage it does to DNA," says Weichselbaum, co-director of the Ludwig Center at the University of Chicago. "But it has recently become increasingly clear that the immune system plays an important--perhaps central--role in destroying tumors subjected to radiotherapy. Our study shows how radiation, DNA damage and the immune response that follows are linked."

Fu, Weichselbaum and their colleagues report that dendritic cells--among the immune system's primary reconnaissance forces--play a central role in the phenomenon. Through studies conducted in mouse models and cell cultures, they show that a protein within these cells named STING is key to activating the immune response to irradiated tumors. STING links the detection of small fragments of DNA to their production of an immune factor known as interferon-β (IFN-β). This factor boosts the ability of dendritic cells to activate the immune system's killer T cells, which destroy cancer cells.

Dendritic cells cruise the body looking for signs of infection or disease, using a variety of biochemical sensors that recognize general molecular patterns associated with different types of pathogens. One such detector, an enzyme known as cGAS, is activated by fragments of double-stranded DNA. cGas is a sensor of viral DNA that also senses damaged DNA from irradiated cells, thereby drawing the immune system into the host response to anti-tumor radiation.

The researchers show that cGAS in dendritic cells gets activated by such DNA fragments--an event that in turn switches on STING. This initiates a cascade of biochemical signals that culminates in the production of IFN-β, which promotes the activation of killer T cells by dendritic cells.

"This seems to be a fairly specific response in the context of radiation," says Weichselbaum. "If you knock out the STING gene in mice, their tumor growth is similar to that of normal mice. But, in the knock-out mice, the tumors are far more resistant to radiation than the tumors of control mice.

The team's experiments show that the dendritic cells from these STING knock-out mice fail to activate killer T cells following tumor irradiation. That capability, they find, can be restored by the addition of IFN-β.

Similarly, dendritic cells from mice whose cGAS genes were shut down or knocked out also failed to activate anti-tumor T cells. The cells regained that ability when given a dose of the molecules produced by cGAS that switch on STING signaling. Importantly, when those STING-activating molecules were injected into the tumors of normal mice, the tumors became very sensitive to radiation.

"These findings could open the door to improving cancer therapy," says Weichselbaum. "Drugs that activate STING signaling or the induction of IFN-β could be used to boost the effects of radiotherapy on tumors. Those effects might be observed in chemotherapy as well, since it too causes significant DNA damage."

In the longer term, says Weichselbaum, such molecules could be combined with existing killer T cell-boosting immunotherapies or cancer vaccines and radiation treatment to generate potent, systemic immune responses against metastatic cancers. He and his colleagues will be assessing these possibilities in mice.

This study was supported by the US National Institutes of Health, Ludwig Cancer Research and The Foglia Foundation.

About Ludwig Cancer Research

Ludwig Cancer Research is an international collaborative network of acclaimed scientists with a 40-year legacy of pioneering cancer discoveries. Ludwig combines basic research with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested more than $2.5 billion in life-changing cancer research through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers.

For further information please contact Rachel Steinhardt, rsteinhardt@licr.org or +1-646-371-7394.

Rachel Steinhardt | EurekAlert!
Further information:
http://www.licr.org/

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Nonstop Tranport of Cargo in Nanomachines

Max Planck researchers revel the nano-structure of molecular trains and the reason for smooth transport in cellular antennas.

Moving around, sensing the extracellular environment, and signaling to other cells are important for a cell to function properly. Responsible for those tasks...

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Optical Coherence Tomography: German-Japanese Research Alliance hosted Medical Imaging Conference

19.11.2018 | Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

 
Latest News

Nonstop Tranport of Cargo in Nanomachines

20.11.2018 | Life Sciences

Researchers find social cultures in chimpanzees

20.11.2018 | Life Sciences

When AI and optoelectronics meet: Researchers take control of light properties

20.11.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>